Last update July 30, 2022

Ambrisentan

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is a selective antagonist of the endothelin receptor (ARE) of the propanoic acid group. Indicated in the treatment of idiopathic pulmonary arterial hypertension or associated with connective tissue disease. Single daily dose oral administration.

At the date of the last update, there was no published data available on its excretion in human milk.

Its pharmacokinetic data (high percentage of protein binding and acid pKa) make it unlikely for it to pass into the mothers’ milk in a clinically significant amount.

It is a generally well-tolerated medication with infrequent or serious side effects. (Wei 2016, Frampton 2011)

Its use in Pediatrics is unauthorized.

Until more information is known about this drug in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in the event of prematurity.

Alternatives

  • Bosentan (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Ambrisentan in other languages or writings:

Tradenames

Main tradenames from several countries containing Ambrisentan in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 378 daltons
Protein Binding 99 %
pKa 3.59 -
Tmax 1.5 (1 - 2) hours
15 (13.6 – 16.5) hours

References

  1. AEMPS. Ambrisentán. Ficha técnica. 2019 Full text (in our servers)
  2. Apotex. Ambrisentan. Drug Summary. 2018 Full text (in our servers)
  3. Wei A, Gu Z, Li J, Liu X, Wu X, Han Y, Pu J. Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials. J Am Heart Assoc. 2016 Oct 26;5(11). pii: e003896. Review. Abstract
  4. Frampton JE. Ambrisentan. Am J Cardiovasc Drugs. 2011 Aug 1;11(4):215-26. Abstract

Total visits

581

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by AELAMA of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM